Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study.

Cancer Immunol Immunother · 2025 · PMC12081789 · PMID 40372486

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference in hematologic AEs between the two groups did not reach statistical significance, the ABVD regimen showed a numerically higher incidence of leukopenia and neutropenia compared to the anti-PD1-AVD regimen.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.